Rivaroxaban for prevention and treatment of venous thromboembolism-Reference-Cited by-同舟云学术

Rivaroxaban for prevention and treatment of venous thromboembolism

Published:2019-03 Issue:2 Volume:15 Page:63-77
ISSN:1479-6678
Container-title:Future Cardiology
language:en
Short-container-title:Future Cardiology

Author:

Chan Noel C¹²,Weitz Jeffrey I¹²

Affiliation:

1. Thrombosis & Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada

2. Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Abstract

Until recently, heparins and vitamin K antagonists (VKAs) were the cornerstones for prevention and treatment of venous thromboembolism (VTE). This situation changed with the introduction of the direct oral anticoagulants, which are now replacing low-molecular-weight heparin for thromboprophylaxis after elective hip or knee arthroplasty and VKAs for VTE treatment. Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment. This paper provides the rationale for factor Xa as a target for anticoagulants, describes the development of rivaroxaban, reviews its pharmacological profile, discusses the clinical trials with rivaroxaban for VTE prevention and treatment and highlights areas of uncertainty.

Publisher

Future Medicine Ltd

Subject

Cardiology and Cardiovascular Medicine,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fca-2018-0076

Reference61 articles.

1. Thrombosis

2. Addressing the burden of hospital-related venous thromboembolism: the role of extended anticoagulant prophylaxis

3. Evolving Treatments for Arterial and Venous Thrombosis

4. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study;Advances in Therapy;2023-11-21

2. A nomogram model for predicting lower extremity deep vein thrombosis after gynecologic laparoscopic surgery: a retrospective cohort study;PeerJ;2023-09-21

3. Applications of electrochemical techniques for determination of anticoagulant drug (Rivaroxaban) in real samples;Biosensors and Bioelectronics;2022-07

4. Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial;Clinical and Applied Thrombosis/Hemostasis;2022-01

5. Developing LC–MS/MS methods to quantify rivaroxabanin human plasma and urine: application to therapeuticdrug monitoring;Biomedical Chromatography;2021-12-29